Anti-TIM-3 plus PD-1 blockade achieves 52% response rate in Hodgkin lymphoma that failed prior immunotherapy.
Phase Ib study of TQB2618 (anti-TIM-3) + penpulimab (anti-PD-1) in 21 r/r cHL patients with prior PD-1/PD-L1 failure: 52% ORR (1 CR, 10 PR). TRAEs in 86%, grade ≥3 in 24%. Median duration of response and OS not reached at 14.1-month median follow-up.
Anti-TIM-3 plus PD-1 blockade achieves 52% response rate in Hodgkin lymphoma that failed prior immunotherapy.
Phase Ib study of TQB2618 (anti-TIM-3) + penpulimab (anti-PD-1) in 21 r/r cHL patients with prior PD-1/PD-L1 failure: 52% ORR (1 CR, 10 PR). TRAEs in 86%, grade ≥3 in 24%. Median duration of response and OS not reached at 14.1-month median follow-up.
Key Findings
- 52% ORR in r/r cHL after PD-1/PD-L1 therapy failure
- 1 complete response and 10 partial responses in 21 patients
- TRAEs in 86% of patients; grade ≥3 in 24%—manageable toxicity
- Median duration of response and OS not yet reached at 14 months
- TQB2618 600mg Q3W selected as recommended Phase 2 dose
Implications
TIM-3 blockade shows meaningful activity in cHL resistant to standard checkpoint inhibition. Larger Phase 2 study warranted.
Caveats
Phase Ib; small (n=21); single-arm; abstract-only. Chinese multicenter study—validation in diverse populations needed.
Source: Journal for immunotherapy of cancer — 2026-04-10
